Salt Lake City, Utah headquartered Myriad Genetics Inc.'s stock edged 0.30% lower, to close the day at $16.64. The stock recorded a trading volume of 997,646 shares. Shares of the Company, which focuses on the development and marketing of predictive, personalized, and prognostic medicine tests worldwide, are trading 11.98% and 41.76% below its 50-day and 200-day moving averages, respectively. Additionally, the stock traded at a PE ratio of 12.62 and has a Relative Strength Index (RSI) of 38.61. MYGN complete research report is just a click away and free at:
On Thursday, shares in Venlo, the Netherlands headquartered Qiagen N.V. ended the session 1.57% lower at $26.89 with a total volume of 1.05 million shares traded. Qiagen's shares have gained 10.16% in the last one month, 1.63% in the previous three months, and 1.82% in the past one year. Shares of the Company, which provides sample to insight solutions that transform biological samples into valuable molecular insights worldwide, are trading at a PE ratio of 54.00. The stock is trading 0.78% above its 50-day moving average and 11.67% above its 200-day moving average. Moreover, the Company's shares have an RSI of 46.92.
On November 3rd, 2016, research firm Bank of America/Merrill upgraded the Company's stock rating from 'Underperform' to 'Neutral'. The complimentary report on QGEN can be downloaded at:
On Thursday, shares in Raleigh, North Carolina headquartered INC Research Holdings Inc. recorded a trading volume of 524,866 shares, which was higher than their three months average volume of 508,960 shares. The stock ended the day 1.72% lower at $48.65. Shares of the Company are trading at a PE ratio of 25.93. INC Research's stock has advanced 5.76% in the last one month, 11.02% in the previous three months, and 12.15% in the past one year. The Company is trading above its 50-day and 200-day moving averages by 4.02% and 10.79%, respectively. Furthermore, shares of INC Research Holdings, which provides various clinical development services for the biopharmaceutical and medical device industries, have an RSI of 49.90. Sign up for your complimentary research report on INCR at:
Irving, Texas headquartered La Quinta Holdings Inc.'s stock finished Thursday's session 7.41% higher at $13.04 with a total volume of 2.80 million shares traded. Over the last one month and the previous three months, La Quinta's shares have gained 28.85% and 13.59%, respectively. Shares of the Company, which owns, operates, and franchises select-service hotels under the La Quinta brand, are trading at a PE ratio of 183.66. The Company's shares are trading above its 50-day and 200-day moving averages by 19.50% and 12.84%, respectively. La Quinta's stock has an RSI of 83.37. Get free access to your research report on LQ at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA